Gilead Sciences

GILD
Delayed Nasdaq - 07/19 09:59:59 pm
65.04USD
-3.23%
Prev.67.2100
Open67.5200
High67.5300
Low64.9100
Volume8 876 391
Financials
Sales 2019 22 022 M
EBIT 2019 11 470 M
Net income 2019 7 013 M
Debt 2019 2 514 M
Yield 2019 3,87%
P/E ratio 2019 11,9x
P/E ratio 2020 11,8x
EV / Sales2019 3,87x
EV / Sales2020 3,54x
Capitalization 82 702 M
Company
Gilead Sciences specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98%): for the treatment of HIV, hepatitis B virus and hepatitis C virus (98.5% of net sales) and other (1.5%; primarily...
Sector :
Bio Therapeutic Drugs
Calendar :
2019-07-21 Presentation
Trading Rating :
Investor Rating :
Latest news
07/19GILEAD SCIENCES : Murad Ali Shah says his government working hard to contain spread of HIV - Press Note issued by Chief Minister House, Sindh
AQ
07/19SINDH GOVT ALLOCATES RS 600M TO CONTROL SPREAD OF HIV : CM Sindh
AQ
07/19Gilead Licenses Respiratory, Herpes Antiviral Research Programs From Novartis
DJ
07/19GILEAD SCIENCES : Licenses Respiratory and Herpes Antiviral Research Programs From Novartis
BU
07/19GILEAD SCIENCES : Sindh govt allocates Rs600m to contain HIV, says Murad
AQ
07/18GILEAD SCIENCES INC : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
AQ
07/18GILEAD SCIENCES : to Present New Data on HIV Prevention, Treatment and Cure Research at IAS 2019
BU
07/18GILEAD SCIENCES : Chief Scientific Officer John McHutchison to Leave the Company
AQ
Technical analysis trends
Short TermMid-TermLong Term
TrendBearishNeutralNeutral
Resistance67,270,177,2
Spread/Res.-3,2%-7,2%-16%
Spread/Supp.0,26%5,1%5,1%
Support64,961,961,9